The head of Roche Diagnostics North America region, which is headquartered in Indianapolis, has been promoted to oversee the Switzerland-based company’s entire diagnostics division.
Matt Sause, president and CEO of Roche Diagnostics North America since 2019, has been named CEO of Roche Diagnostics and a member of the corporate executive committee.
The move is effective Jan. 1. Sause, who is based in Indianapolis, will relocate to the parent company’s offices in Basel, Switzerland.
Sause succeeds Thomas Schinecker, who was named Roche CEO.
Roche did not name a replacement for Sause in Indianapolis.
“Matt Sause’s career at Roche has spanned 20 years in multiple countries across Asia, Latin America, Europe and North America in both the Diagnostics and Pharma divisions. His combination of scientific knowledge with commercial experience makes him an excellent leader for the Diagnostics division,” said Schinecker.
Sause is no stranger to the Roche Group. In Roche’s diagnostics division from 2002 to 2014, Sause worked in sales roles in the United States, commercial operations in Asia and country leadership in Ireland. In the pharmaceuticals division from 2014 to 2019, he was president of country operations in Peru and Korea before becoming vice president for Roche’s cancer medicine Tecentriq in San Francisco, part of the company’s Genentech subsidiary.
Sause earned a bachelor’s degree in microbiology from Miami University in Ohio and an MBA from the University of California at San Diego.
Roche, based in Switzerland, employs about 3,000 people on its large campus at 9115 Hague Road on the city’s north side. It makes machines and software to help physicians, hospitals and laboratories analyze data and diagnose patients, along with machines and test strips for diabetes patients.